tradingkey.logo
tradingkey.logo
Suchen

Biofrontera Inc

BFRI
Zur Watchlist hinzufügen
1.010USD
0.0000.00%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
11.76MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Biofrontera Inc Unternehmen

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

Biofrontera Inc Informationen

BörsenkürzelBFRI
Name des UnternehmensBiofrontera Inc
IPO-datumOct 14, 2021
CEOLuebbert (Hermann)
Anzahl der mitarbeiter92
WertpapierartOrdinary Share
GeschäftsjahresendeOct 14
Addresse120 Presidential Way,
StadtWOBURN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01801
Telefon17812451325
Websitehttps://www.biofrontera-us.com/
BörsenkürzelBFRI
IPO-datumOct 14, 2021
CEOLuebbert (Hermann)

Führungskräfte von Biofrontera Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
290.21K
+47.38%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
175.00K
+50.00%
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Mr. George Jones
Mr. George Jones
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
290.21K
+47.38%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
175.00K
+50.00%
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Biofrontera Inc?

Die fünf größten Anteilseigner von Biofrontera Inc sind: Prof. Dr. Hermann Luebbert, Ph.D.

Wie viele Institutionen halten Anteile an Biofrontera Inc (BFRI)?

Mit Stand vom 2026Q1 halten 37 Institutionen Anteile an Biofrontera Inc, mit einem Gesamtmarktwert von etwa 2.75M, was 22.90% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -276665.00 gestiegen.